Until recently, Bionano Genomics (BNGO) was a name flying under Wall Street’s radar. Yet, investors have taken a shine to the life sciences company in the past year and in tandem with some mighty share gains, there is a growing awareness that the company could be a force to be reckoned with in the field of cytogenetics.
The latest analyst to present investors with the opportunity is BTIG’s Sung Ji Nam.
“We believe BNGO is on the cusp of disrupting the cytogenetics testing market…
Source link
